INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer&#39;s disease.

sabirnetug IV (ACU193 IV) - Acumen Pharma

http://www.ncbi.nlm.nih.gov/pubmed/39800458

Eric Siemers; Erika N Cline; Gopalan Sethuraman; Hao Zhang; Jasna Jerecic; Karen Sundell; Kimball Johnson; Lawrence S Honig; Michael G Dodds; Mirjam N Trame; Reisa Sperling; Stephen Salloway; Todd Feaster; Vladimir Skljarevski

Jan 13, 2025